Boston, MA 7/27/06—PerkinElmer has acquired two companies for a total of$56.7 million to add to its Genetic Screening business. It has acquired N.N.Macri Technologies, which holds patents related to free beta Human Chori-onic Gonadotropin (free Beta hCG), a peptide hormone recognized as abiomarker for trimester prenatal risk assessment. PerkinElmer also has acquired NTD Laboratories, a reference lab specializing in prenatal risk assessment that had $15 million in revenues for the fiscal year ended in June. “We expect this agreement will accelerate PerkinElmer’s own maternal health research and development initiatives, by giving us the ability to better understand first-hand the needs of the clinical community,” said Robert F. Friel,president of PerkinElmer Life and Analytical Sciences.